U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 121 - 130 of 1608 results

Status:
Investigational
Source:
INN:dimetholizine
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Dimetholizine has antihypertensive activity. It is an antihistaminic agent too. Histamine H1 receptor was predicted as a primary target for dimetholizine. Moreover, it was found to bind the Dopamine D2 and 5-HT1A receptors. Dimetholizine was predicted to be alpha1D-Adrenergic blocker.
Status:
Investigational
Source:
INN:efletirizine
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)



Efletirizine is histamine H1 receptor antagonist. Restricted to topical use. It was under investigation in Phase III (in Europe) clinical studies for the treatment of allergic rhinitis and chronic idiopathic urticarial. Research was discontinued in 2005 due to limited clinical efficacy and safety data. Efletirizine also reduced ocular itching.
Status:
Investigational
Source:
INN:tibenelast
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Tibenelast is an orally active phosphodiesterase inhibitor that was undergoing phase II clinical trials in the USA as a bronchodilator. In preclinical studies Tibenelast is moderately active against the lung and stomach enzyme while being a very weak inhibitor of the heart enzyme and it does not inhibit enzymes involved in arachidonic acid metabolism. Tibenelast shows potent anti-anaphylactic activity in guinea pigs without cardiovascular effects at the bronchodilatory doses.
Status:
Investigational
Source:
INN:levomequitazine [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Levomequitazine is the L-enantiomer of mequitazine. The antihistaminergic activity mainly resides in the S-enantiomer, L-mequitazine, whereas the anticholinergic activity mainly resides in the D-enantiomer. It was shown, that L-enantiomer of mequitazine is less potent antagonist of human M3 muscarinic acetylcholine receptors than D-enantiomer. In vitro binding studies have shown that the affinity of L-mequitazine for H1 receptors is approximately ten times higher and to muscarinic receptors ten times lower, compared to d-mequitazine. Memory impairment was observed after administration of L-mequitazine 10 mg alone on delayed recall. This could be due to indirect effects of H1 receptor blockade. L-mequitazine 10 mg produced mild driving impairment, whereas L-mequitazine 2.5 and 5.0 mg show no effects on driving. Levomequitazine had been in phase III clinical trials by Pierre Fabre for the treatment of perennial allergic rhinitis and seasonal allergic rhinitis.
Status:
Investigational
Source:
INN:clocinizine
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)


Clocinizine is an antihistamine derivative of diphenylmethylpiperazine. Clocinizine is a competitive and reversible H1 receptor antagonist. The drug is marketed in Spain under tradename Senioral in combination with phenylpropanolamine for temporary relief of nasal congestion in colds, rhinitis, and sinusitis.
Status:
Investigational
Source:
INN:mapinastine
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Mapinastine (E 4716) is a selective antagonist of histamine H1 receptors. In animal models, mapinastine exerts antiallergic and anti-asthmatic properties. It demonstrated a lack of central effects. Mapinastine development has been discontinued.
Status:
Investigational
Source:
INN:etoloxamine [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Etoloxamine is an antihistamine.
Status:
Investigational
Source:
INN:minocromil
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Minocromil was studied as a histamine receptor antagonist for the treatment of asthma. However, further development of the drug was discontinued.
Status:
Investigational
Source:
INN:cycliramine [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Cycliramine is a substituted piperidine derivative discovered by Schering Corp. The drug is claimed to have antihistamine, antispasmodic, antiacetylcholine and analgesic activity.
Status:
Investigational
Source:
USAN:Altoqualine
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Altoqualine (458L) is a derivative of benzylisoquinoline, it inhibited kidney histidine decarboxylase and decreased the passive anaphylactic bronchospasm in guinea pigs. Altoqualine is an antihistamine and antiallergic agent.